Wednesday November 25 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Ascenta Therapeutics Inc.

Nil


Contact Details:
11455 EI Camino Real,Suite 460
San Diego
California
92130
United States of America
Tel:858-436-1200
Fax:858-436-1201
Email:info@ascenta.com
WWW:

www.ascenta.com/




Loading...

Press Releases on Ascenta Therapeutics Inc.:

BioPortfolio Logo
Ascenta Therapeutics Announces Presentation of Results From a Dose-Ranging Study of AT-101 With Standard Therapy in Patients With Glioblastoma Multiforme 26th October, 2009 Ascenta Therapeutics, Inc.
MALVERN, Pa., Oct. 26 /PRNewswire/ -- Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral,
Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 1st June, 2009 Ascenta Therapeutics
MALVERN, Pa., June 1 /PRNewswire/ -- Ascenta Therapeutics announced today that promising results from ongoing clinical studies in prostate, brain and lung cancers were among the data presented on AT
Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 26th May, 2009 Ascenta Therapeutics
MALVERN, Pa., May 26 /PRNewswire/ -- Ascenta Therapeutics announced today that eleven presentations or publications on pre-clinical and clinical studies of AT-101, an oral, pan-Bcl-2 inhibitor, in
Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models 21st April, 2009 Ascenta Therapeutics, Inc.
- Data on novel pro-apoptotic agent presented at the 100th Annual Meeting of the American Association for Cancer Research - - University of Pennsylvania data on chemotherapy resistance patterns in
Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer 27th February, 2009 Ascenta Therapeutics
- Data presented today at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium - MALVERN, Pa., Feb. 27 /PRNewswire/ -- Ascenta Therapeutics announced today positive

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 424 times since April 2007, the link to the organisation's website has been followed 71 times

Recent Search Terms used to find this page: ascenta Therapeutics | Ascenta Therapeutics Inc | .

Search for more companies in San Diego

Search for more companies in California



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Ascenta Therapeutics Inc.

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.